View Cart  

FDA Funds Comparison Study of Prograf vs. Generic Counterparts

The FDA has given $2.7 million to University of Cincinnati researchers to study whether generic versions of the transplant drug Prograf have the same efficacy as Astellas Pharma’s branded product.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00